Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination
Open Access
- 13 July 2004
- journal article
- highlights
- Published by Wiley in European Journal of Immunology
- Vol. 34 (8) , 2072-2083
Abstract
Preliminary observations of humoral immunity against the myelin oligodendrocyte glycoprotein (MOG) in experimental allergic encephalomyelitis (EAE) and human multiple sclerosis (MS) suggest that a subset of anti‐MOG autoantibodies directed against conformational epitopes is of pathogenic predominance. Here, we provide proof that in marmoset EAE, autoantibodies reactive against conformational epitopes of MOG are not only responsible for aggravating demyelination, but also an essential factor for disease dissemination in space within the central nervous system, a hallmark for typicalforms of human MS. In terms of effector mechanisms, IgG deposition and complement activation occur exclusively in association with presence of these conformational antibodies, while microglial/macrophage activation appears to be a common immunopathological finding regardless of the fine determinant specificity of anti‐MOG antibodies. These findings highlight for the first time the complex heterogeneity of function and pathogenicity in the polyclonal anti‐MOG antibody repertoire of outbred species. Because the linear and conformational antibody determinants of MOG are shared between marmosets and humans, these results are directly relevant to understanding effector mechanisms of organ damage in MS.See accompanying Commentary http//dx.doi.org/10.1002/eji.200425291Keywords
This publication has 39 references indexed in Scilit:
- Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating EventNew England Journal of Medicine, 2003
- Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelinationAnnals of Neurology, 1998
- A Conformational Study of the Human and Rat Encephalitogenic Myelin Oligodendrocyte Glycoprotein Peptides 35–55European Journal of Biochemistry, 1997
- Antibody response in Lewis rats injected with myelin oligodendrocyte glycoprotein derived peptidesInternational Immunology, 1996
- The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis ratJournal of Neuroimmunology, 1995
- Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.Journal of Clinical Investigation, 1995
- Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controlsJournal of Neuroimmunology, 1991
- IMMUNOCYTOCHEMICAL LOCALIZATION OF THE TERMINAL COMPLEMENT COMPLEX IN MULTIPLE SCLEROSISNeuropathology and Applied Neurobiology, 1989
- Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturationJournal of Neuroimmunology, 1989
- Tumor Necrosis Factor Mediates Myelin Damage in Organotypic Cultures of Nervous TissueaAnnals of the New York Academy of Sciences, 1988